Potential of Metabolic MRI to Address Unmet Clinical Needs in Localised Kidney Cancer.

Ines Horvat-Menih, Grant D Stewart, Ferdia A Gallagher

Abstract readReview

In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ines Horvat-MenihDepartment of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.ORCID 0000-0002-1373-6944

Grant D StewartDepartment of Surgery, University of Cambridge, Cambridge CB2 0QQ, UK.ORCID 0000-0003-3188-9140

Ferdia A GallagherDepartment of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.ORCID 0000-0003-4784-5230

Funding

Cancer Research UK Cambridge Centre RQAG/119CRUK C19212/A27150CRUK EDDPMA-May22\100068NIHR Cambridge BRC BRC 1215 20014

6 · The paper itself

Abstract

Renal cell carcinoma (RCC) is a major global health issue with an increasing incidence and mortality rate. Current diagnostic methods are either invasive or limited in their ability to accurately differentiate between benign and malignant tumours and to predict early treatment response. This can lead to incorrect diagnosis, delayed treatment, patient anxiety, and suboptimal outcomes. RCC subtypes are known to exhibit distinct metabolic alterations, for example in glucose metabolism. These metabolic phenotypes offer potential targets for non-invasive imaging techniques to improve diagnosis and treatment, but current clinically available metabolic imaging tools such as

Indexed as

deuterium metabolic imaginghyperpolarised [1-13C]pyruvate MRImetabolic heterogeneityrenal cell carcinomarenal mass biopsyrenal oncocytomasodium MRItreatment response

Identifiers

PMID40507256

DOI10.3390/cancers17111773

PMCPMC12153877

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.